Charles Lieber, AP

Em­bat­tled Har­vard sci­en­tist Charles Lieber goes on a counter-of­fen­sive, hir­ing high-pro­file lawyer and su­ing Har­vard for aban­don­ing him amid fed­er­al probe

Charles Lieber, the Har­vard sci­en­tist fac­ing fed­er­al charges for al­leged­ly ly­ing about Chi­nese fund­ing, is mount­ing a fierce le­gal de­fense, be­gin­ning with the en­list­ment of a high-pro­file at­tor­ney and a law­suit against his em­ploy­er.

Marc L. Mukasey

Lieber hired Marc Mukasey, a crim­i­nal at­tor­ney who de­fend­ed for­mer Navy Seal Ed­ward Gal­lagher against war crime charges last year and cur­rent­ly rep­re­sents Er­ic Trump in a New York state fraud case, the New York Times first re­port­ed. And on Fri­day, he filed suit against Har­vard, al­leg­ing the uni­ver­si­ty aban­doned him and their re­spon­si­bil­i­ty to in­dem­ni­fy him or aid his le­gal de­fense.

The le­gal ma­neu­ver­ing sets Lieber apart from the oth­er re­searchers caught up in the Jus­tice De­part­ment’s ef­fort to weed out sci­en­tists it claims were si­phon­ing re­search from the US to Chi­na, un­der the so-called Thou­sand Tal­ents pro­gram. The drag­net had large­ly caught up grad­u­ate stu­dents and pro­fes­sors of Chi­nese ori­gin, some of whom left the coun­try or oth­er­wise did not con­test charges in court.

Lieber was ar­rest­ed in Jan­u­ary on charges of ly­ing to the US gov­ern­ment about re­ceiv­ing mil­lions of dol­lars from the Chi­nese state and par­tic­i­pat­ing in a Chi­nese tal­ent re­cruit­ment pro­gram, while NIH and DoD spent over $15 mil­lion fund­ing his lab. The tenured pro­fes­sor, a pi­o­neer in med­ical nan­otech­nol­o­gy and the chair of Har­vard’s chem­istry de­part­ment, plead­ed not guilty on Ju­ly 30.

The new law­suit ar­gues that Har­vard ben­e­fit­ed from years of Lieber’s re­search, on­ly to dis­tance them­selves en­tire­ly when fed­er­al of­fi­cials rolled in. He is cur­rent­ly on paid leave from the uni­ver­si­ty.

Pros­e­cu­tors say Lieber signed an agree­ment to be­come a “strate­gic sci­en­tist” at the Wuhan Uni­ver­si­ty of Tech­nol­o­gy in Chi­na, a po­si­tion that grant­ed him $200,000 per year in liv­ing ex­pens­es and salary and an­oth­er $1.5 mil­lion to open a sec­ond lab in the Chi­nese city. They added that he was se­lect­ed for Thou­sand Tal­ents — a pro­gram meant to re­cruit top for­eign sci­en­tists that fed­er­al of­fi­cials say was a con­duit to steal­ing re­search — in 2012 but claimed to have nev­er tak­en part in the pro­gram when he was in­ter­viewed by fed­er­al of­fi­cials in 2018.

He could face more than 10 years in prison for fail­ing to dis­close the Chi­nese fund­ing, fil­ing false tax re­turns and fail­ing to re­port a for­eign bank ac­count.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Fireside chat between Hal Barron and John Carroll, UKBIO19

It’s time we talked about bio­phar­ma — live in Lon­don next week

Zoom can only go so far. And I think at this stage, we’ve all tested the limits of staying in touch — virtually. So I’m particularly happy now that we’ve revved up the travel machine to point myself to London for the first time in several years.

Whatever events we have lined up, we’ve always built in plenty of opportunities for all of us to get together and talk. For London, live, I plan to be right out front, meeting with and chatting with the small crowd of biopharma people we are hosting on October 12 at Silicon Valley Bank’s London headquarters. And there’s a lengthy mixer at the end I’m most looking forward to, with several networking openings between sessions.

Car­olyn Bertozzi (Illustration: Assistant editor Kathy Wong for Endpoints News)

Car­olyn Bertozzi, re­peat biotech founder and launch­er of a field, shares in chem­istry No­bel win

Carolyn Bertozzi, predicted by some to become a Nobel laureate, clinched one of the world’s top awards in the wee hours of Wednesday, winning the Nobel Prize in Chemistry alongside a repeat winner and a Copenhagen researcher.

The Stanford professor, Morten Meldal of University of Copenhagen and 2001-awardee K. Barry Sharpless of Scripps shared the prize equally. The Nobel is sometimes split in quarters and/or halves.

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Takeda on Tuesday morning made an announcement that almost 3,000 people with the rare disease known as hypoparathyroidism were fearing.

Due to unresolved supply issues and manufacturing woes, Takeda said it will cut its losses and discontinue its hypoparathyroidism drug, known as Natpara (parathyroid hormone), halting all manufacturing of the drug by the end of 2024, but the entire inventory will be available until depleted or expired, a company spokesperson said via email.

Pfizer and BioNTech's original Marvel comic book links evolving Covid vaccine science to Avengers' evolving villain-fighting tools.(Source: Pfizer LinkedIn post)

Pfiz­er, BioN­Tech part­ner with Mar­vel for Avengers and Covid-fight­ing com­ic book

Pfizer and BioNTech are collaborating with Marvel to celebrate “everyday” people getting Covid-19 vaccines in a custom comic book.

In the “Everyday Heroes” digital comic book, an evolving Ultron, one of the Avengers’ leading villains, is defeated by Captain America, Ironman and others. The plotline and history of Ultron is explained by a grandfather who is waiting with his family at a clinic for Covid-19 vaccinations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

FDA+ roundup: Ad­comm date set for Cy­to­ki­net­ics heart drug; New gener­ic drug guid­ance to re­duce fa­cil­i­ty de­lays

The FDA has set Dec. 13 as the day that its Cardiovascular and Renal Drugs Advisory Committee will review Cytokinetics’ potential heart drug, setting up a key vote ahead of a Feb. 28, 2023 PDUFA date.

The drug, known as omecamtiv mecarbil, read out its first Phase III in November 2020, hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as the key to breaking into the market, failing to significantly differ in reducing cardiovascular death from placebo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Robert Arch, OncoSec Medical CEO

Pen­ny stock, Mer­ck part­ner lays off 45% of staff to reach PhII read­out by ear­ly 2023

Another biotech is feeling the chill of the bear market, laying off staff in an effort to preserve cash.

Cancer immunotherapy startup OncoSec Medical announced Tuesday evening it would lay off about 45% of its workforce, or 18 employees, it estimated in an SEC filing. OncoSec made the move to better position the company to complete a Phase II trial for its sole program in melanoma, CEO Robert Arch said in a statement.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

New Chroma Medicine board member Jeff Marrazzo

Jeff Mar­raz­zo has found a buzzy new biotech cause to cham­pi­on. And once again, he's all in

Jeff Marrazzo is one of those biotech execs who has always been focused on the next big goal. He has a track record for meeting objectives, relentlessly staying on message, and breaking new ground.

The fact that he stayed around for a couple of years after Roche’s $4.3 billion Spark buyout, making sure the organization he founded weathered Covid-19, is one example. And that came after he carefully guided the company to the first-ever US approval of a gene therapy — no easy task.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.